RYTM - リズム・ファ―マシュ―ティカルズ (Rhythm Pharmaceuticals Inc.) リズム・ファ―マシュ―ティカルズ

 RYTMのチャート


 RYTMの企業情報

symbol RYTM
会社名 Rhythm Pharmaceuticals Inc (リズム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 リズム・ファーマシューティカルズ(Rhythm Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は、生命を脅かす代謝障害をもたらす希少な遺伝的欠陥の治療用ペプチド治療薬の開発と商品化に注力する。同社のリードペプチド製品候補は、稀な遺伝性肥満疾患の治療用のメラノコルチン-4受容体、またはMC4Rアゴニストというセメラノイドである。セルトメラノイドは、メラノコルチン-4またはMC4経路欠損の治療用補充療法として役立つ。MC4経路欠損は、体内の満腹信号およびエネルギー恒常性の崩壊をもたらし、ひいては飢餓・肥満の激しい感情につながる。また、6つの単一の遺伝子関連、または一遺伝子性のMC4経路欠損プロオピオメラノコルチン、またはPOMC、レプチン受容体、またはLepR、Bardet-Biedl症候群、Alstrom症候群、POMCヘテロ接合体及びPOMCエピジェネティック障害に関連する肥満に重点を置いた。   リズム・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、生命を脅かす代謝障害を引き起こす遺伝的疾患に対するペプチド治療薬の開発・商業化に従事する。主な新薬候補はセメラノイド(RM-493)で、MC4経路の欠損によって起こる稀な遺伝的肥満疾患の治療に使用され、6種類の疾患において評価する。本社所在地はマサチュ―セッツ州ボストン。   Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.
本社所在地 500 Boylston Street 11th Floor Boston MA 02116 USA
代表者氏名 David P. Meeker David P. Meeker
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-264-4280
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.rhythmtx.com
nasdaq_url https://www.nasdaq.com/symbol/rytm
adr_tso
EBITDA EBITDA(百万ドル) -51.05400
終値(lastsale) 26.23
時価総額(marketcap) 896413843.51
時価総額 時価総額(百万ドル) 950.75230
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 663.19830
当期純利益 当期純利益(百万ドル) -52.91900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rhythm Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 99% to $30.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.60 to -$1.12.

 RYTMのテクニカル分析


 RYTMのニュース

   Rhythm Pharmaceuticals Inc. (RYTM) Forecast: Revisiting The Past To Gain Insights For The Future  2021/12/04 15:00:00 Stocks Register
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) concluded the trading at $8.83 on Friday, December 03 with a fall of -4.02% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.20 and 5Y monthly beta was reading 1.43 with its price kept floating in the Rhythm Pharmaceuticals Inc. (RYTM) Forecast: Revisiting The Past To Gain Insights For The Future Read More »
   Millennium Management LLC Trims Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)  2021/11/30 10:26:45 Transcript Daily
Millennium Management LLC lowered its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 13.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,816 shares of the companys stock after selling 23,711 shares during the period. Millennium Management []
   Credit Suisse AG Sells 1,654 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)  2021/11/28 09:44:44 Transcript Daily
Credit Suisse AG trimmed its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 23,802 shares of the companys stock after selling 1,654 shares during the quarter. Credit Suisse AGs holdings in Rhythm Pharmaceuticals were worth $467,000 []
   Charles Schwab Investment Management Inc. Buys 15,409 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)  2021/11/22 10:36:42 Transcript Daily
Charles Schwab Investment Management Inc. raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,631 shares of the companys stock after acquiring an additional 15,409 shares during the quarter. Charles Schwab Investment Management []
   Charles Schwab Investment Management Inc. Has $5.24 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)  2021/11/22 09:40:42 Transcript Daily
Charles Schwab Investment Management Inc. increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 267,631 shares of the companys stock after buying an additional 15,409 shares during the period. Charles Schwab Investment Management Inc.s holdings in []
   Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference  2021/11/09 21:01:00 Intrado Digital Media
BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 11:20 a.m. ET.
   Macquarie Group Ltd. Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)  2021/11/09 09:56:44 Transcript Daily
Macquarie Group Ltd. lifted its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 313.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,930 shares of the companys stock after purchasing an additional 1,463 shares during the quarter. Macquarie Group Ltd.s holdings in Rhythm Pharmaceuticals []
   Samsara BioCapital LLC Increases Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)  2021/11/07 17:24:42 Transcript Daily
Samsara BioCapital LLC increased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 49.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 300,293 shares of the companys stock after purchasing an additional 99,247 shares during the period. Rhythm Pharmaceuticals makes up about 0.7% of Samsara BioCapital []
   Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Earnings Results, Beats Expectations By $0.13 EPS  2021/11/05 00:50:42 Dakota Financial News
Rhythm Pharmaceuticals (NASDAQ:RYTM) issued its earnings results on Tuesday. The company reported ($0.70) earnings per share for the quarter, beating the Zacks consensus estimate of ($0.83) by $0.13, MarketWatch Earnings reports. During the same period last year, the firm posted ($0.77) earnings per share. NASDAQ RYTM traded down $0.33 during trading hours on Thursday, reaching []
   Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Earnings Beat  2021/11/04 08:46:41 Dakota Financial News
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $12.10, but opened at $12.64. Rhythm Pharmaceuticals shares last traded at $12.65, with a volume of 706 shares traded. The company reported ($0.70) EPS for the quarter, []
   Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference  2021/05/27 12:00:00 GlobeNewswire
BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12 noon ET.
   Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference - May 27, 2021  2021/05/27 00:00:00 BioSpace
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12 noon ET.
   Rhythm Pharma Receives Positive CHMP Opinion For Setmelanotide - Quick Facts  2021/05/21 12:59:04 Business Insider Markets
(RTTNews) - Biopharmaceutical company Rhythm Pharmaceuticals, Inc. (RYTM) announced Friday that the European Medicines Agency''s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for setmelanotide for the treatment of obesity and the control of hunger associated with
   Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency  2021/05/21 12:53:00 FinanzNachrichten
European Commission decision anticipated in JulyBOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to trans
   Rhythm Pharmaceuticals gets positive CHMP opinion for obesity treatment setmelanotide  2021/05/21 12:50:17 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リズム・ファ―マシュ―ティカルズ RYTM Rhythm Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)